Showing recent highlights
What's New
PubMed (Open Access Guidelines) · December 1, 2026
A study looked at data from over 17,000 people with early-stage breast cancer to compare different chemotherapy combinations and schedules. Researchers found that certain combinations and timing of chemotherapy drugs — specifically giving some drugs together versus one after another — appeared to work better at helping people stay cancer-free and live longer. People with early-stage breast cancer may want to ask their doctor how the timing and combination of their chemotherapy plan compares to the latest research findings.
Lifestyle
PubMed · July 24, 2026
Researchers found that breast cancer patients going through chemotherapy who practiced Neiyanggong — a traditional Chinese mind-body exercise that combines slow, gentle movements with quiet, focused stillness — reported significantly less fatigue and better sleep than those who did not practice it. Patients followed a gradually progressing Neiyanggong program across three chemotherapy cycles, and by the end of the third cycle, the improvements in tiredness, time to fall asleep, sleep efficiency, and daytime functioning were notably stronger in the exercise group. The study involved 72 patients split into two groups, with one group adding this structured movement practice on top of their regular care.
What's New
PubMed · July 23, 2026
A study found that breast cancer patients who received a special nutritional formula by mouth starting the day after surgery — on top of a healthy diet — had better nutritional health and stronger immune function one week later compared to patients who only followed the standard diet. This matters because surgery after chemotherapy can leave the body depleted, and good nutrition during recovery may help the immune system — the body's natural defense system — bounce back more quickly. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · July 23, 2026
A systematic review looked at 21 sets of clinical guidelines related to care for breast cancer survivors and found that most of them clustered around three key areas: watching for signs that cancer might come back, screening for new cancers, and managing health concerns related to fertility, hormones, and sexual health. The review also noted that survivorship care — the ongoing care people receive after breast cancer treatment — is not always delivered consistently or in line with established standards. This kind of research helps healthcare teams identify where clearer, more unified guidance could improve the long-term care breast cancer survivors receive from their doctors.
What's New
PubMed · July 20, 2026
Researchers found that in people with a specific type of early breast cancer — one that is hormone receptor-positive and HER2-positive (meaning the cancer cells have certain proteins that help them grow) — skipping chemotherapy and instead using targeted therapy plus hormone-blocking treatment still led to excellent survival rates five years later, with 100% of patients in that group alive compared to about 98% in the chemotherapy group. This is notable because chemotherapy often comes with difficult side effects, so finding that some patients might do just as well without it could be meaningful for their quality of life. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 20, 2026
Researchers found that for people with a common type of breast cancer (called hormone receptor-positive, HER2-negative) whose cancer had started growing again despite treatment, continuing the same targeted drug — abemaciclib — while switching the hormone-blocking medication paired with it showed some benefit, particularly for those who switched to a hormone therapy called fulvestrant. In that group, the cancer took a median of about 7 months to start growing again, compared to about 3 months in those who switched to a different hormone therapy. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 17, 2026
Researchers found that combining a drug that blocks certain immune-suppressing cells (called macrophages) in tumors with chemotherapy showed promise for people with a hard-to-treat form of breast cancer called triple-negative breast cancer, where cancer has spread to other parts of the body. In the study, nearly 45% of patients saw some benefit, and the combination also seemed to help the immune system become more active — which could make another type of treatment called immunotherapy (drugs that help the body's own defenses fight cancer) work better. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 15, 2026
Researchers found that women with breast cancer are significantly more likely to experience anxiety, depression, and stress compared to women without the disease — in fact, their risk of anxiety alone was about 37% higher. This matters because these mental health challenges can seriously affect a person's overall sense of well-being and quality of life during an already difficult time. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 15, 2026
Researchers found that when doctors rely only on prescription refill records to check whether breast cancer patients are taking their oral cancer medications as prescribed, they may overestimate how consistently patients are actually taking them — because picking up a prescription doesn't always mean taking the medication. The study also found that using more than one method to check medication-taking habits at the same time caught significantly more patients who were struggling to stick to their treatment, jumping from about half to nearly 70%. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 15, 2026
A study found that postmenopausal women with breast cancer whose tumors tested positive for a protein called the progesterone receptor (PR) — which helps cancer cells grow — appeared to benefit significantly from a hormone-blocking medication called tamoxifen over a 25-year period, with fewer cases of the cancer spreading compared to those who didn't take it. Women whose tumors were PR-negative, meaning the protein wasn't present, didn't seem to experience the same benefit from tamoxifen. This is early research and hasn't yet changed treatment guidelines.
Lifestyle
PubMed (Open Access Guidelines) · July 14, 2026
Researchers found that women who closely followed the Mediterranean diet — an eating pattern rich in vegetables, fruits, whole grains, legumes, fish, and olive oil, eaten regularly as a daily habit — were less likely to develop breast cancer and, among those already diagnosed, had better survival outcomes. The study also found that sticking to this diet helped reduce body weight and improve blood sugar control in women with breast cancer. These findings suggest the diet may offer meaningful benefits, though researchers note the evidence is still building.
What's New
PubMed · July 14, 2026
Researchers found that a smartphone app called 'Ruaikang,' designed to encourage women at high risk for breast cancer to get screened, was practical to use and well-received by participants. Women who used the app showed early signs of being more willing to get screened and felt more confident about understanding breast cancer and their own health. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 13, 2026
Researchers found that for women with early-stage breast cancer receiving a common chemotherapy drug called paclitaxel, skipping a steroid medication called dexamethasone after the first two doses appeared to be safe — no serious allergic reactions occurred, and cancer outcomes looked similar between those who kept taking it and those who stopped. This matters because dexamethasone is routinely given alongside paclitaxel to prevent allergic reactions, but taking it repeatedly over time can cause unwanted side effects like blood sugar changes, sleep problems, and hormonal shifts. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 9, 2026
Researchers found that a digital health tool called RecoverEsupport — designed to guide breast cancer patients through recovery steps after surgery, like moving around early, eating and drinking sooner, and managing pain — showed promising signs of being both practical to use and acceptable to patients. The idea is that having a digital support tool could help people follow through on important recovery habits that are easy to skip or forget, which matters because doing these things well can reduce complications and help people get to their next phase of treatment faster. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · July 8, 2026
A study found that eribulin (brand name Halaven) worked about as well as two other chemotherapy drugs — docetaxel and paclitaxel — when used together with trastuzumab (Herceptin) and pertuzumab (Perjeta) as a first treatment for a specific type of breast cancer called HER2-positive, meaning the cancer cells have a protein that makes them grow faster. Researchers found that people taking eribulin felt their quality of life get worse more slowly — about 7.8 months compared to 4.7 months with docetaxel — which suggests it may be easier to tolerate day-to-day, even though it did cause more low white blood cell counts (called neutropenia), which can make it harder for the body to fight infections. This appears to be a new option, as the study positions eribulin as a comparable alternative to the standard chemotherapy choices for this type of advanced breast cancer.
What's New
PubMed · July 6, 2026
Researchers found that a particularly aggressive form of breast cancer — called triple-negative breast cancer, meaning it lacks three common markers that doctors normally use to target treatment — may look genetically different in South Asian women compared to women in Western countries. Specifically, studies from India and Pakistan found that changes in genes called BRCA1, BRCA2, and TP53, which normally help repair DNA and protect against cancer, appeared frequently in these patients, with BRCA1 changes showing up especially often in Pakistani women — a pattern that could one day help doctors choose more targeted treatments for this group. This is early research and hasn't yet changed treatment guidelines.
Medications
PubMed · July 6, 2026
A study found that a drug called sacituzumab govitecan (also known as Trodelvy) was tested in Japanese patients with a specific type of breast cancer that had already been treated before — one that is hormone receptor-positive and HER2-negative, meaning the cancer grows in response to hormones but not a protein called HER2. Researchers found that in some patients the cancer shrank or stopped growing for a period of time, with patients living a median of 13 months overall, though the main response-rate goal of the study was not formally met. This represents an emerging option being studied for this group of patients, and nearly all participants experienced side effects — some of them serious — so this is not a new approved treatment in Japan but rather an early look at how well and how safely the drug works in a Japanese population.
What's New
PubMed · July 4, 2026
Researchers found that among people with breast cancer dealing with exhaustion that doesn't go away — a very common and draining problem called cancer-related fatigue — three non-drug approaches stood out as most helpful: Tai Chi Chih (a gentle, slow-movement practice), cognitive behavioral therapy (a type of talk therapy that helps change unhelpful thought patterns), and massage therapy. The study compared 21 different non-drug options across 26 studies involving nearly 3,000 patients, and all three of these approaches showed meaningful reductions in fatigue compared to receiving no special treatment. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 4, 2026
Researchers found that taking CoQ10 — a natural supplement that supports energy production in cells — alongside a common breast cancer chemotherapy drug called paclitaxel may help reduce some of the drug's side effects. In a study of 60 people with breast cancer, those who took CoQ10 were less likely to develop significant nerve damage in their hands or feet (68% vs. 96%), and when nerve symptoms did appear, they took longer to show up — about 30 days compared to 20 days in those who didn't take CoQ10. People taking CoQ10 also reported less fatigue, sleep problems, digestive issues, and joint and muscle pain as treatment went on. This is early research and hasn't yet changed treatment guidelines.
Ask your doctor: Ask the doctor whether taking Coenzyme Q10 supplements alongside paclitaxel chemotherapy might help reduce nerve pain and other side effects the patient might experience during treatment.
What's New
PubMed · July 1, 2026
A study found that a nerve-blocking technique called an erector spinae plane block — where a numbing medication is injected near the spine before breast cancer surgery — did not reduce the chances of patients developing long-lasting pain (pain that sticks around for three to six months after surgery) compared to those who received a placebo injection. However, researchers did find that patients who received the block needed significantly less morphine in the first 24 hours after surgery and reported lower pain levels right after their operation. This matters because long-lasting pain after breast cancer surgery affects a large number of patients and can seriously impact daily life, so finding ways to prevent it is an active area of research — but this is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that for people with early-to-later-stage breast cancer, adding radiation to lymph node areas near the breastbone and collarbone — beyond just the breast itself — may help reduce the chances of cancer spreading or coming back, even in patients whose nearby lymph nodes showed no signs of cancer at the time of surgery. This was especially relevant for people whose tumors were located in the center or inner part of the breast. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that people with a specific type of advanced breast cancer — one that has a DNA repair flaw called homologous recombination deficiency, meaning the cancer cells struggle to fix their own DNA damage — may survive longer with an intensified chemotherapy approach compared to standard treatment. In this study, patients who received the high-dose chemotherapy regimen had a much higher 4-year survival rate than those who received conventional chemotherapy. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
A study found that women with breast cancer who did supervised strength training twice a week during chemotherapy showed increases in certain immune signaling proteins in their blood — while women who didn't exercise saw those same proteins decrease. These proteins, called cytokines, act like messengers that help the body's immune system respond, and the difference between the two groups suggests that staying active during chemotherapy might influence how the immune system behaves. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · July 1, 2026
According to the German Society of Radiation Oncology (DEGRO) guidelines, radiation therapy to the lymph node areas near the breast is recommended after surgery for breast cancer, with the specific approach depending on each patient's situation — for example, whether they received chemotherapy before surgery and how well the tumor responded to it. The guidelines also highlight that some patients may be able to avoid more extensive underarm surgery if radiation is used instead, which could mean a less invasive overall treatment experience. People with breast cancer can talk with their doctor about which combination of surgery and radiation makes the most sense for their individual case.
What's New
PubMed · July 1, 2026
Researchers found that a technique called autologous fat transfer — where fat is taken from one part of the body and used to rebuild the breast after cancer treatment — may be a possible option for breast reconstruction in people who have had radiation therapy. The process typically requires several sessions over time, and the research suggests it may take more sessions for people who have had radiation compared to those who haven't. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that using local numbing medications during breast cancer surgery — whether injected near the skin or given as a nerve-blocking technique — did not appear to affect how long patients lived over a follow-up period of about six and a half years. The study looked at more than 1,600 people with breast cancer and compared those who received these numbing medications during surgery with those who did not, and survival rates were similar across all groups. This is early research and hasn't yet changed treatment guidelines.
Guidelines
PubMed · July 1, 2026
According to the German Working Group on Gynecologic Cancers (AGO) guidelines, updated in March 2026, doctors treating breast cancer patients whose lymph nodes were initially affected but responded well to chemotherapy given before surgery no longer need to remove as many lymph nodes as before. Instead, a more targeted approach — removing only a small number of carefully identified lymph nodes to check for remaining cancer — is now the preferred method. A full lymph node removal is only needed if those checked nodes still show signs of significant cancer, which matters because removing fewer lymph nodes can mean a faster recovery and fewer side effects for patients.
Ask your doctor: Ask the doctor whether the patient should have a targeted axillary dissection instead of a sentinel lymph node biopsy if the patient is getting chemotherapy first to shrink lymph nodes.
What's New
PubMed · July 1, 2026
Researchers found that breast cancer patients who received a shorter, one-week course of radiation therapy — including treatment to the lymph node areas near the breast — reported similar quality of life to patients who had a longer, three-week course, even 18 months later. This matters because a shorter radiation schedule is more convenient for patients, and this study suggests it doesn't come at the cost of feeling worse or experiencing more side effects like arm swelling. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that for some older women with small, early-stage breast cancer, a precise form of radiation treatment — delivered in just five sessions and aimed directly at the tumor — combined with hormone-blocking medication, was able to completely eliminate the cancer in about half of patients, allowing them to skip surgery altogether. Among those who avoided surgery, no breast cancers came back over nearly four years of follow-up, and patients reported no lasting regret about their treatment choice. This is early research and hasn't yet changed treatment guidelines.
What's New
PubMed · July 1, 2026
Researchers found that certain immune cells called tumor-associated macrophages — which normally help protect the body — can actually be "hijacked" by triple-negative breast cancer (an aggressive form that doesn't respond to many common treatments) to help the cancer grow and spread. A review of clinical trials found early signs that treatments targeting these rogue immune cells, especially when combined with chemotherapy or other therapies, may help slow the disease. This is early research and hasn't yet changed treatment guidelines.
For informational purposes only. Not medical advice. Always consult a physician before making any health decisions.